Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Abvc Biopharma (ABVC) over the last 11 years, with Q3 2025 value amounting to $575578.0.

  • Abvc Biopharma's Other Accumulated Expenses rose 3728.1% to $575578.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $575578.0, marking a year-over-year increase of 3728.1%. This contributed to the annual value of $430107.0 for FY2024, which is 14791.03% up from last year.
  • As of Q3 2025, Abvc Biopharma's Other Accumulated Expenses stood at $575578.0, which was up 3728.1% from $728576.0 recorded in Q2 2025.
  • Abvc Biopharma's 5-year Other Accumulated Expenses high stood at $3.2 million for Q1 2022, and its period low was $961.0 during Q4 2022.
  • Its 5-year average for Other Accumulated Expenses is $791812.5, with a median of $430107.0 in 2024.
  • Per our database at Business Quant, Abvc Biopharma's Other Accumulated Expenses plummeted by 9996.7% in 2022 and then surged by 1795338.19% in 2023.
  • Over the past 5 years, Abvc Biopharma's Other Accumulated Expenses (Quarter) stood at $2.9 million in 2021, then tumbled by 99.97% to $961.0 in 2022, then soared by 17953.38% to $173493.0 in 2023, then surged by 147.91% to $430107.0 in 2024, then soared by 33.82% to $575578.0 in 2025.
  • Its Other Accumulated Expenses stands at $575578.0 for Q3 2025, versus $728576.0 for Q2 2025 and $617879.0 for Q1 2025.